Cargando…
Sirolimus as a second-line treatment for Graves’ orbitopathy
OBJECTIVES: A beneficial effect of sirolimus in Graves’ orbitopathy (GO) was reported, suggesting a possible use in clinical practice. We conducted an observational, single-centre, no-profit, clinical study to investigate the efficacy of sirolimus as a second-line treatment for moderate-to-severe, a...
Autores principales: | Lanzolla, G., Maglionico, M. N., Comi, S., Menconi, F., Piaggi, P., Posarelli, C., Figus, M., Marcocci, C., Marinò, M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9525329/ https://www.ncbi.nlm.nih.gov/pubmed/35831587 http://dx.doi.org/10.1007/s40618-022-01862-y |
Ejemplares similares
-
Anti-nuclear autoantibodies in Graves’ disease and Graves’ orbitopathy
por: Lanzolla, G., et al.
Publicado: (2022) -
Beneficial effect of low-dose radioiodine ablation for Graves’ orbitopathy: results of a retrospective study
por: Lanzolla, Giulia, et al.
Publicado: (2021) -
Graves’ disease and Graves’ orbitopathy following COVID-19
por: Lanzolla, G., et al.
Publicado: (2021) -
Antioxidant Therapy in Graves’ Orbitopathy
por: Lanzolla, Giulia, et al.
Publicado: (2020) -
Editorial: News in Graves’ orbitopathy: patients management and treatments
por: Lanzolla, Giulia, et al.
Publicado: (2023)